Clinical calculator summary
Original 2009 CUETO BCG-treated NMIBC score
Clinical calculator summary
Original 2009 CUETO BCG-treated NMIBC score
Separate additive recurrence and progression scores with original 1-, 2-, and 5-year probability tables.
Evidence-based context for fast calculator use
- Purpose:
- Reproduce the original CUETO classification for a complete seven-factor assessment in the source treatment context.
- Population:
- Papillary Ta/T1 urothelial NMIBC treated with the original CUETO BCG schedule; CIS is concomitant rather than isolated.
- Factors:
- Sex, Age group, Primary versus recurrent tumor, Tumor count, Ta versus T1, Associated CIS, WHO 1973 grade
- Reference:
- Fernandez-Gomez J, et al. J Urol. 2009;182(5):2195-2203.
Pin your most used calculators here by clicking the star in the dropdown.
CUETO Risk Score (BCG-Treated)
Clinical Context & Background
This calculator implements the original 2009 Fernandez-Gomez CUETO model for recurrence and progression after intravesical BCG treatment of papillary Ta/T1 non-muscle-invasive bladder cancer. It calculates separate recurrence and progression scores from sex, age group, previous-tumor status, number of tumors, T category, associated carcinoma in situ, and WHO 1973 grade, then reports the original 1-, 2-, and 5-year cohort probabilities.
The model was developed from 1,062 participants in four CUETO randomized trials. The original regimen delivered 12 BCG instillations over approximately 5-6 months after TURBT; the cohort did not routinely receive an immediate postoperative instillation or second TURBT. Contemporary BCG schedules and outcomes may differ.
Use only for appropriately staged Ta/T1 urothelial NMIBC treated with BCG. Associated CIS means concomitant CIS with papillary Ta/T1 disease. Do not apply to isolated primary CIS, muscle-invasive or metastatic disease, upper-tract disease, nonurothelial tumors, or by silently translating modern low/high grade into WHO 1973 G1/G2/G3. The probabilities are historical cohort estimates, not individualized predictions or treatment thresholds.
Primary Source EvidenceFernandez-Gomez J, et al. J Urol. 2009;182(5):2195-2203. doi:10.1016/j.juro.2009.07.016.
Formula Logic
Calculate the original 2009 CUETO recurrence and progression scores separately from all seven required categorical variables, then map each raw total to its published 1-, 2-, and 5-year probability band.Reference Data
| Outcome and score | Historical 1-year probability | Historical 2-year probability | Historical 5-year probability |
|---|---|---|---|
| Recurrence 0-4 | 8.24% | 12.60% | 20.98% |
| Recurrence 5-6 | 12.07% | 22.28% | 35.57% |
| Recurrence 7-9 | 25.36% | 39.61% | 47.65% |
| Recurrence 10-16 | 41.79% | 52.55% | 67.61% |
| Progression 0-4 | 1.17% | 2.16% | 3.76% |
| Progression 5-6 | 3.00% | 4.97% | 11.69% |
| Progression 7-9 | 5.55% | 11.95% | 21.26% |
| Progression 10-14 | 13.97% | 24.81% | 33.57% |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use for appropriately staged papillary Ta/T1 urothelial NMIBC treated with intravesical BCG when all seven original variables are known.
- Use WHO 1973 G1/G2/G3 and record CIS only when associated with a papillary Ta/T1 tumor.
How To Interpret
- Read recurrence and progression as separate scores with separate historical 1-, 2-, and 5-year probability bands.
- Treat the probabilities as cohort observations from the original CUETO trial population, not individualized forecasts or treatment thresholds.
What To Do Next
- Document all seven inputs, both scores, both probability bands, and the treatment context so the result can be reproduced.
- Determine surveillance and treatment separately using current guidance, pathology, treatment history, patient factors, and multidisciplinary assessment.
Limitations
- Not for isolated primary CIS, muscle-invasive or metastatic disease, upper-tract urothelial carcinoma, nonurothelial tumors, or an unconfirmed BCG-treated context.
- Do not substitute WHO 2004/2016 low/high grade for WHO 1973 G1/G2/G3 without an explicit pathological assignment.
- The derivation regimen used 12 BCG instillations over about 5-6 months and did not reflect routine immediate postoperative instillation, second TURBT, or contemporary maintenance schedules.
- Variant histology, lymphovascular invasion, prostatic urethral CIS, incomplete TURBT, and modern re-TURBT findings require separate assessment.
Validated Population
The 1,062-patient CUETO cohort assembled from four randomized BCG trials used for the original 2009 model.
Keep recurrence and progression separate
The same seven findings receive different weights in the two models, so both exact totals and both historical probability bands should be documented.
Calculation verification history
Verified
Calculation verification history
Verified: Production browser revalidation
- Three source-backed cases passed through visible production controls at the minimum scores, the recurrence/progression score-5 transition, and the maximum scores.
- All scores and 1-, 2-, and 5-year probability bands matched, and all seven expanded trace rows displayed defined source decisions.
- The former literal undefined trace defect was absent, with no unexpected N/A, stale control, or browser-console error observed.
Case-level evidence is retained in validation/browser-revalidation/bladder-cancer-cueto-bcg-score-2026-08-03.json.
: Local browser remediation verification
- Ten source-backed cases passed through visible local browser controls across 11 submissions after the shared result-trace correction.
- The run covered minimum and maximum totals, every recurrence/progression probability-band boundary, all seven factor branches, required-field validation, and reset/repeat behavior.
- All seven visible factor rows displayed defined values while recurrence and progression remained separate, with no literal undefined or NaN. The original production findings remain open until deployment and public revalidation.
Case-level local remediation evidence is retained in validation/browser-production/bladder-cancer-cueto-bcg-score.local-remediation.json.
: Production browser validation
- Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
- Overall browser status: failed-ui-console. high: Every valid result renders literal undefined after each of the seven factor rows in the expanded clinical-summary trace, despite correct scores and probabilities. | medium: Production emitted minified React error #418 during route load.
- Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.
Case-level production evidence is retained in validation/browser-production/bladder-cancer-cueto-bcg-score.json.
: Full validation test
- 1,536/1,536 source-weight, probability-table, all-combination, boundary, malformed-input, UI, trace, scope, report, registry, and isolation checks passed.
- No registered master panel calculates CUETO; no panel receives inherited verification.
: Calculation and input-contract correction
- Corrected the separate recurrence and progression weights, restored distinct WHO 1973 G1/G2/G3 categories, and restored the original 1-, 2-, and 5-year probability tables and raw score bands.
- Removed favorable defaults, point-coded inputs, coercion, traffic-light treatment labels, and individualized advice; added strict seven-field semantics and the original BCG schedule and applicability context.
Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.
Related Tools
Frequently Asked Questions
Are recurrence and progression calculated with the same points?
No. The original CUETO model applies separate weights to the same seven variables and produces separate totals.
Can modern low/high grade be entered instead of WHO 1973 grade?
No. The source model requires an explicit WHO 1973 G1, G2, or G3 assignment.
Do the probabilities determine BCG duration or cystectomy?
No. They are historical cohort observations and do not independently prescribe treatment or surveillance.
Evidence-based oncology decision support. Verify with clinical guidelines.